Fujifilm Diosynth Biotechnologies has broken ground on a major expansion of its large scale biologics production facility in Denmark.
This facility involves an investment of $928m (JPY100bn), which was announced by FUJIFILM Corporation in June 2020.
Go deeper with GlobalData
FUJIFILM Diosynth Biotechnologies is a contract development and manufacturing organisation (CDMO) for biologics, viral vaccines and viral vectors.
This expansion will double the current production capacity of bulk drug substance with the addition of 6 x 20,000L bioreactors, thereby taking the total to 12 x 20,000-liter bioreactors.
The new construction project will also feature a completely automated, fill/finish capability to support large-scale production of up to around 35 million units per annum.
See Also:
FUJIFILM Diosynth Biotechnologies will add 300 positions in Denmark by the end of 2023 to support the expansion.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThis expansion will also include a new packaging line intended to assemble several kinds of auto-injectors and automatic labelling. These capabilities will become operational in spring 2022.
The fill/finish production line is expected to come onstream by summer 2023, while the large scale cell bulk drug substance expansion is expected to become operational by the end of 2023.
FUJIFILM Bio CDMO Division GM and senior executive vice president Takatoshi Ishikawa said: “Fujifilm has highlighted the CDMO business as a priority growth area, and is actively investing in technology to expand its manufacturing capacity to meet the growing demands of customers.
“Additionally, as Fujifilm’s largest investment in Europe for Bio CDMO business, this new facility represents our commitment to growing our Bio CDMO offering in the region to better serve our customers.”
FUJIFILM Denmark COO and senior vice president Lars Petersen said: “The expansion will be transformative, significantly expanding our ability to support current and future partners, infusing sustainability efforts into future operations, and further strengthening our leadership in biologic drug substance manufacturing. We are excited to see the site grow and to welcome 300 new employees.”
—————————————————————————————————————-
Image: Turning of the soil at FUJIFILM Diosynth Biotechnologies in Denmark to signal the start of the expansion project. Credit: FUJIFILM Diosynth Biotechnologies
